1,14 adjusted_prevalence_ratioThe adjusted prevalence ratio for cervical cancer screening in intervention clinics compared to control clinics was 1.14 (95% CI 0.74–1.75) when adjusted for having at least one provider trained to perform cervical cancer screening at baseline.
Kenyacancer du col de l'utéruspublié 2023Implementation science : ISeurope_pmcdocument de 5 observationsDOI 10.1186/s13012-023-01322-y
7 %As of October 2021, 7% of Fahari ya Jamii project-supported HIV clinics in Nairobi and Kajiado Counties were treating visual inspection with acetic acid (VIA) positive lesions.
Kenyacancer du col de l'utérusobservé October 2021publié 2025BMC women's healthPubMeddocument de 8 observations
36,4 %Thirty-six point four percent (36.4%) of the respondents obtained information about cervical cancer from media.
Kenyacancer du col de l'utéruspublié 2016Journals & Books Hosting (International Knowledge Sharing Platform)OpenAlexdocument de 18 observations
16 757 screeningsThere were a total of 16,757 cervical cancer screenings or rescreenings documented across the 19 study sites in Siaya and Busia counties of Kenya from September 2021 to September 2022.
Kenyacancer du col de l'utérusobservé September 2021 to September 2022publié 2025JCO global oncologyPubMeddocument de 3 observations
3 000 deathsIn Kenya, over 3,000 women died from cervical cancer in 2020.
Kenyacancer du col de l'utérusobservé 2020publié 2023PloS onePubMeddocument de 16 observations
2,43 aPRIn rural Kenya, microfinance members had an adjusted prevalence ratio of 2.43 for cervical cancer screening compared to non-members.
Kenyacancer du col de l'utérusobservé November 2018 to March 2019publié 2020BMC health services researchPubMeddocument de 2 observations
9,5 %In Eldoret, cervical cancer incidence increased significantly by 9.5% annually from 2002 to 2016.
Kenyacancer du col de l'utérusobservé 2002-2016publié 2020British journal of cancereurope_pmcdocument de 5 observations
29,4 %Cervical cancer screening uptake among women living with HIV in western Kenya was 29.4% during the study period from October 2007 to February 2019.
Kenyacancer du col de l'utérusobservé October 2007 to February 2019publié 2024JCO global oncologyPubMeddocument de 6 observations
320 000 casesWe estimated 320,000 cases attributed to cervical cancer over the lifetimes of the 14 evaluated birth cohorts.
Kenyacancer du col de l'utéruspublié 2023VaccinePubMeddocument de 6 observations
50,6 yearsThe mean age at diagnosis was 50.6 years.
Kenyacancer du col de l'utéruspublié 2023BMC cancerPubMeddocument de 12 observations
40 %Positive lymph nodes were the most common high-risk feature, occurring in 40.0% of HIV-negative patients.
Kenyacancer du col de l'utérusobservé 2014–2023publié 2026BMC cancerPubMeddocument de 16 observations
48,6 %HPV DNA self-sampling accounted for 48.6% of cervical cancer screening tests.
Kenyacancer du col de l'utéruspublié 2026BMC cancerPubMeddocument de 12 observations
45 %The 2-year survival probability after diagnosis of cervical cancer was 45%.
Kenyacancer du col de l'utéruspublié 2023BMC cancerPubMeddocument de 12 observations
1 per_317Among 317 women, invasive cervical cancer controls included HPV16 and 66 coinfection in 1/317 (0.3%).
Kenyacancer du col de l'utéruspublié 2021BioMed research internationalPubMeddocument de 9 observations
43,6 %Forty-three point six percent (41/94) of the respondents who had ever been screened perceived cervical screening procedures as uncomfortable.
Kenyacancer du col de l'utéruspublié 2016Journals & Books Hosting (International Knowledge Sharing Platform)OpenAlexdocument de 18 observations
9,43 hazard_rate_ratioIn patients with cervical cancer, no cancer-directed therapy was associated with substantially worse overall survival (hazard rate ratio, 9.43; 95% confidence interval, 3.03–29.33).
Kenyacancer du col de l'utéruspublié 2021The oncologisteurope_pmcdocument de 14 observationsDOI 10.1002/onco.13718
27 %Cervical cancer screening uptake among women living with HIV was 27.0% in the AMPATH program during the study period from October 2007 to February 2019.
Kenyacancer du col de l'utérusobservé October 2007 to February 2019publié 2024JCO global oncologyPubMeddocument de 6 observations
50 %In Kenya, nearly 50% of women diagnosed with cervical cancer are diagnosed late.
Kenyacancer du col de l'utéruspublié 2026BMC research notesPubMeddocument de 7 observations
46,1 per_100000Cervical cancer had an age-standardized incidence rate (ASR) of 46.1 per 100,000 among women in Nairobi during 2004–2008.
Kenyacancer du col de l'utérusobservé 2004-2008publié 2015International journal of cancereurope_pmcdocument de 9 observations
84 %Clinics that reported cervical cancer screening were much more likely to have at least one provider trained to perform cervical cancer screening (84%, 32/38) compared to clinics that did not report screening (28%, 9/32; PR 3.77, 95%CI 1.82-7.83).
Kenyacancer du col de l'utérusobservé 2017-2018publié 2022BMC health services researcheurope_pmcdocument de 10 observationsDOI 10.1186/s12913-022-08984-2
16,667 %Only one in six patients with cervical cancer in sub-Saharan Africa received cancer-directed therapy with curative potential.
Kenyacancer du col de l'utéruspublié 2021The oncologisteurope_pmcdocument de 14 observationsDOI 10.1002/onco.13718
85 %Cervical cancer awareness was 85.0% among mothers of adolescent girls in Western Kenya.
Kenyacancer du col de l'utéruspublié 2021The Pan African medical journalPubMeddocument de 5 observations
14,5 monthsThe median overall survival was 14.5 months among people living with HIV.
Kenyacancer du col de l'utérusobservé 2014–2023publié 2026BMC cancerPubMeddocument de 16 observations
46,9 %Adherence to treatment guidelines was not assessed in 46.9% of patients.
Kenyacancer du col de l'utéruspublié 2021The oncologisteurope_pmcdocument de 14 observationsDOI 10.1002/onco.13718
Dialogue-based educational intervention by trained community health volunteers significantly improved cervical cancer knowledge among women of reproductive age (p < 0.001).
Kenyacancer du col de l'utéruspublié 2024BMC women's healthPubMeddocument de 3 observations
Chaque ligne mène à son document source. Le nombre indiqué est celui des observations VALIDÉES qu'il porte, jamais celui des observations extraites : les deux diffèrent sur la plupart des documents. L'extrait exact du texte source n'est pas publié, par contrainte de droit d'auteur.